<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04130178</url>
  </required_header>
  <id_info>
    <org_study_id>4/10/2019</org_study_id>
    <nct_id>NCT04130178</nct_id>
  </id_info>
  <brief_title>Nerve Block of the Proximal Interphalangeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study</brief_title>
  <official_title>Nerve Block of the Proximal Interphalyngeal Joints PIPs in Rheumatoid Arthritis (RA) Patients: a Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers will include 83 rheumatoid arthritis patients (either early or established)
      diagnosed after 2010 ACR/EULAR criteria with bilateral hand arthritis aged 18 or above. Nerve
      block to the neural bundle of the 2nd and 3rd PIPs will be done to one hand (the dominant in
      half of the participants and the non-dominant in the remaining). The other hand will be used
      as a control. Half ml of Bupivacaine will be injected through a 27G needle at the level of
      the volar proximal digital crease of the 2nd and 3rd PIP. The needle will be directed
      alternatively toward the two pedicles on both sides.

      PIPs of the 2nd and 3rd fingers in both hands will be examined EULAR-OMERACT scoring system
      at 0, 2 weeks and 2 months intervals. Visual analogue scale (VAS) for each hand will be used
      at the same intervals. There is no certain conditions for medications and all the patients
      were using sDMARDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PIPs of the 2nd and 3rd fingers at the control group will be injected with .5 mL of
      triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) for each joint through a 27G
      needle
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Actual">January 25, 2020</completion_date>
  <primary_completion_date type="Actual">January 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain</measure>
    <time_frame>0 time after 2 weeks and after 2 months</time_frame>
    <description>by visual analogue sclae</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the degree of inflammation</measure>
    <time_frame>at 0 time after 2 weeks and after 2 months</time_frame>
    <description>Musculoskeletal ultrasound evaluation by EULAR-OMERACT score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Bupivacine injected</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Half ml of Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was injected through a 27G needle at the level of the volar proximal digital crease of the 2nd and 3rd PIP on each side of the selected joint.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacine spared</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bupivicaine hydrochloride .5% (Marcaine, Pfizer) was not injected in this group and it was considered as a control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nerve block</intervention_name>
    <description>block of the digital nerves in rheumatoid arthritis patient</description>
    <arm_group_label>Bupivacine injected</arm_group_label>
    <arm_group_label>Bupivacine spared</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid arthritis patient according to ACR/EULAR criteria

          -  age &gt;18

          -  bilateral hand affection

        Exclusion Criteria:

          -  peripheral neuropathy

          -  other chronic arthritis

          -  patient who did mastectomy or any other hand operation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elsaman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sohag University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sohag university</name>
      <address>
        <city>Sohag</city>
        <zip>82749</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ahmed Mahrous</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

